AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.
A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the ...
Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...
More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...
More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...
Researchers from The Ohio State University and the Indian Institute of Technology Madras have developed an artificial intelligence framework to rapidly generate drug-like molecules that are easier to ...
February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...
An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how ...
An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The work, published ...
Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector-from its initial emergence and growth to fundamental ...
The real “commercial launch” happens years before launch preparation officially begins. Once Phase III begins, your evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results